• Immunomedics Inc., of Morris Plains, N.J., was granted U.S. Patent No. 8,105,596, titled "Immunotherapy of B-cell malignancies using anti-CD22 antibodies." It covers therapeutic compositions comprising any combination of conjugated or unconjugated anti-CD20 and anti-CD22 antibodies.